1. Introduction {#sec1}
===============

Spinal cord injury (SCI) is a debilitating condition affecting an estimated three million people worldwide, with approximately 180,000 new cases each year ([@bib29]). The devastating impacts of SCI include medical, functional, and socioeconomic sequela which play a lifelong role in the care of these patients. In addition to the resulting physical limitations, mechanical, toxic, or ischemic lesions of the white matter tracts of the spinal cord in SCI may be either temporary or permanent, and associated with severe motor, sensory and autonomic dysfunction ([@bib6]). A recent meta-analysis across 17 studies and involving 2529 SCI patients found that chronic pain was common among secondary complaints to SCI; 53% of all SCI patients reported neuropathic pain was distressing and debilitating, leading to worsened quality of life, depression, and poor sleep quality ([@bib12]). In the same meta-analysis, it was reported that post-SCI neuropathic pain most frequently presents at or below vertebral-level injury ([@bib12]; [@bib9]), which is rated by patients as the most 'severe pain' of all pain experienced in the post-injury state ([@bib49]).

In addition to the personal, patient-level burden caused by debilitating post-SCI neuropathic pain, larger costs to the health care system loom ([@bib12]). A well-controlled study of 3524 commercially insured SCI patients with neuropathic pain matched to 3524 SCI patients without neuropathic pain in similar insurance schemes were retrospectively reviewed 12 months after neuropathic pain onset for resources used, cost incurred, and hospitalization ([@bib32]). When compared to individuals without post-SCI neuropathic pain, those patients with post-SCI neuropathic pain visited physicians and emergency departments more often and required procedures and prescriptions for neuropathic pain that exceeded their matched counterparts by \$17,369 per annum per patient ([@bib32]).

Post-SCI neuropathic pain is treated with conventional pharmacotherapeutic pain management techniques, often with limited success in meaningful pain reductions that stabilize or improve quality of life ([@bib48]; [@bib13]; [@bib12]). In other neuropathic pain conditions, such as failed back surgery syndrome (FBSS) and complex regional pain syndrome (CRPS), spinal cord stimulation (SCS) is supported by high-quality class 1 evidence for chronic pain of the back and lower limbs ([@bib7]; [@bib4]; [@bib56]; [@bib38]; [@bib39]), and indicated for peripheral vascular disease and severe angina pectoris in Europe ([@bib5]; [@bib57]). Neuromodulation therapy with SCS has been used to achieve pain reduction outcomes superior to conventional pharmacotherapeutic pain management ([@bib27]), which has been shown durable in some patients up to 8 years after implantation and device activation ([@bib8]).

[@bib3] distinguish the management of chronic pain using SCS from other so-called "peripheral" forms of electrical stimulation that do not directly target white matter tracts of the central nervous system by applying the terms 'intraspinal stimulation' (IS) and 'extraspinal stimulation' (ES), to each of the different stimulation modalities, respectively. Where IS targets specific nerves and neural tissue in the spinal cord, the percutaneous ES modality targets extraspinal nerves -- wherever the neuropathic pain region is thought to be ([@bib3]; [@bib2]).

[@bib20] published the first randomized crossover study of stimulation (acute) of the subcutaneous tissues in the back for low back pain, calling the technique "percutaneous electrical nerve stimulation" (PENS). Various iterations on this name have been used in studies of chronic subcutaneous peripheral stimulation with permanent device implantation for pain relief from the early 2000s, including "peripheral subcutaneous electrostimulation/neurostimulation" ([@bib51]; [@bib45]), "subcutaneous peripheral nerve stimulation" (SQ PNS) ([@bib28]; [@bib52], [@bib53]; [@bib42]; [@bib11]), "subcutaneous targeted neuromodulation" (STN) ([@bib22]; [@bib55], [@bib54]), and "subcutaneous targeted stimulation" (STS) ([@bib47]).

More recently, the terms "peripheral nerve field stimulation" (PNFS) ([@bib43]; [@bib44]; [@bib59]; [@bib46]; [@bib34]; [@bib16]; [@bib14]) and "peripheral subcutaneous field stimulation" (PSFS) ([@bib31]; [@bib33]; [@bib61]; [@bib37]; [@bib24]), the suggested standardized nomenclature of [@bib2], have been used to denote the procedure whereby electrode(s) are inserted percutaneously into the peripheral (non-spinal) subcutaneous space near regions of chronic pain to elicit paresthesias to mask chronic neuropathic pain. Although similar in surgical procedure and naming convention, "peripheral nerve stimulation" (PNS), another studies form of ES for chronic pain management, and PSFS differ in that the former (PNS) aims to induce paresthesia along a single nerve and its innervated regions, while PSFS aims to spread a paresthesia "field" across any number of neuropathic fibers in a region of chronic pain, not an identified neural structure, via an electric field generated around the electrode\'s activated subcutaneous bipoles ([@bib2]). Although the mechanisms of PSFS have not been completely elucidated, there is evidence that electrical stimulation of large A-β fibers modulates the flow of afferent pain information from A-δ and smaller C fibers ([@bib17]), which may lead to local membrane depolarization and release of anti-inflammatory molecules ([@bib41]). Clinicians have reported successful pain reduction using both high- (50--150 Hz) and low-frequency (1--10 Hz) PSFS, suggesting mechanisms of action that differ from transcutaneous nerve stimulation ([@bib2]).

PSFS may prove particularly useful in targeting regions of pain where conventional SCS use has been shown to be ineffective or limited, including the face, thorax, cervico-dorsal and lumbar areas, and other sacral, abdominal, and inguinal regions ([@bib45]). This perceived advantage of peripheral lead placement in PSFS has led to a recent surge in successful reports of its use in treatment of chronic pain of the back ([Table 1](#tbl1){ref-type="table"}) ([@bib11]; [@bib14]; [@bib22]; [@bib26]; [@bib28]; [@bib34]; [@bib36]; [@bib42]; [@bib44]; [@bib45]; [@bib46]; [@bib47]; [@bib58]; [@bib59]; [@bib62]), face ([@bib61]), knee/joints ([@bib33]), abdomen ([@bib43]), pelvis ([@bib52]), shoulder ([@bib55]; [@bib53]), and in cases of refractory angina ([@bib24]), post-thoracotomy pain ([@bib53]; [@bib54]; [@bib14]), and post-operative inguinal pain ([@bib51]).Table 1Previous studies of peripheral subcutaneous field stimulation (PSFS) for intractable back pain.Table 1PublicationStudy designIntervention terminologyN (back pain pts)Pain type/known etiologyFollow-up durationPain outcome(s)Notes[@bib22]Retrospective reviewSTN2Costovertebral angle tenderness (CVAT); post-lobectomy painPt 1: 3 years\
Pt 2: 26 monthsPt 1: Baseline VAS 9/10 reduced 95%\
Pt 2: Baseline VAS 10/10 reduced 100%Both pts stopped analgesics;\
1--2 h of stim (\<10 Hz and \<3 mA) per day provided 12--24 h relief[@bib44]Retrospective reviewPNFS65/6 failed back surgery syndrome (FBSS);\
1 chronic back pain of unknow etiology, but previous SCS failureReported range of follow-ups:\
0--12 months6/6 patients reported significant reductions in pain on VAS, and reductions in analgesicsMost used parameters: 30--102 Hz, 250--500 μs[@bib28]Retrospective reviewPNS1FBSS1 yearBaseline VAS 7/10 reduced to 1/10, stopped analgesics[@bib42]Retrospective reviewSQ PNS1FBSS, epidural fibrosis, with previous SCS failure, and previous PSFS percutaneous lead failure1 yearReported pain relief of 95% from baseline (with paddle lead)Pt failed SCS, failed PSFS with percutaneous leads at L4/S1 after 3 mo of stim (increasing to 3 V). Replaced with 1 paddle lead at L5 for 1 yr at amplitude 0.5 V[@bib45]Retrospective reviewPSNS2Unknown paravertebral pain; lumbo-sacral spondylo-arthrosis (stenosis) with previous SCS failure1 yearPt 1: Baseline VAS 10/10 reduced to 4/10\
Pt 2: Baseline VAS 10/10 reduced to 2/10Stimulation parameters:\
2--2.5 V, 20 Hz, 300 msec[@bib58]Retrospective reviewPNS1311 FBSS;\
2 chronic low back pain (CLBP)6.5 ± 3.39 monthsBaseline avg. VAS 7.42 ± 1.16\
Follow-up.: 3.92 ± 1.727/13 pts reported decrease in analgesics[@bib47]Multicenter retrospective reviewSTS7037 FBSS;\
29 CLBP;\
4 thoracic back pain3 monthsFBSS baseline NRS avg:\
8.0 ± 1.4\
Follow-up avg: 3.3 ± 2.1\
CLBP baseline NRS avg:\
8.3 ± 0.9\
Follow-up avg: 4.2 ± 2.2\
Thoracic pain baseline NRS avg: 8.8 ± 1.5\
Follow-up avg: 2.5 ± 0.618% pts reduced analgesic consumption, and additional 12% pts stopped analgesic use. Reduction in analgesics most pronounced in FBSS patients.\
Most used parameters:\
50--100 Hz, 210--450 μs, 0.5--2.9 V[@bib59]Prospective, observational studyPNFS5244 lumbosacral pain of various etiologies;\
8 thoracic back pain of various etiologies8.1 ± 4.7 monthsBaseline NRS avg.: 7.4 ± 1.7\
Follow-up: 3.2 ± 2.369% pts had relief \>50%;\
72% pts reduced analgesics[@bib62]Retrospective reviewPNFS18Post-laminectomy syndrome (PLS)1 yearBaseline VAS avg:\
7.44 ± 1.04\
Follow-up avg: 1.67 ± 0.605 pts reduced analgesics; 11 pts stop analgesics;\
Parameters: 1.8--3.2 V, 250--450 μs, 40--50 Hz[@bib11]Retrospective reviewSQ PNS6FBSS4.5 months (range 2--9 mo)Avg. percent pain relief from baseline at follow-up: 45% (range 20--80%)Only 1 pt reduced analgesic intake at follow-up; parameter:\
0--6.4 V, 210--450 μs[@bib34]Prospective, multicenter randomized controlled studyPNFS23Axial pain (cervical, dorsal, lumbosacral)1 yearBaseline VAS avg: 7.8 ± 1.1\
Follow-up: 2.5 ± 2.4\
16/23 (69%) of pts responded (\>50% pain relief) at 1 yr80% responded (\>50% pain relief) to active stim during randomized, crossover trial (4--8 day periods for each condition);\
10 pts reduced analgesics[@bib26]Prospective, multicenter observational studyPNFS40Lumbosacral pain of various etiologies6 monthsBaseline VAS 7.6 ± 1.52\
1 mo: 3.85 ± 2.24 (n = 40)\
6 mo: 4.36 ± 2.31 (n = 28)\
44% avg. pain reduction at 6 mos.65 pts received combination SCS + PSFS therapy with statistically equivalent VAS score reductions (results not shown here)[@bib36]Prospective case seriesPNFS20Thoracic pain of various etiologies1 yearBaseline NRS avg.: 7.75 ± 1.4\
Follow-up: 2.25 ± 2.14 (n = 17)\
Avg. pain relief 72.41% ± 21.69% (range 55.6%--100%)10 pts reduced analgesic; 3 pts explanted before follow-up (1 pain at IPG site, 1 recurrent lead infection, 1 non-responder)[@bib14]Retrospective reviewPNFS6FBSS60 monthsBaseline VAS avg: 9.66\
Follow-up: 4.66Significant reduction in analgesics after PSFS; greatest responder rate in lumbosacral pain FBSS;\
Parameters:210--310 μs, 20--30 Hz, 3.2 mA[^1]

Neuromodulation therapy for the treatment of post-spinal cord injury neuropathic pain has been proposed in the literature but rarely reported on ([@bib18]). The authors identified only one case of PSFS for post-SCI intractable pain in the literature ([@bib37]). [@bib37] utilize a combination therapy of SCS and PSFS in 40 patients with varying etiologies of chronic back pain, most of whom are failed back surgery syndrome (FBSS) patients (n = 26), and one post-SCI neuropathic pain patient. The aim of [@bib37] study is to resolve an implantation procedure and programming paradigm for combination SCS and PSFS therapy. The authors do not report individual outcomes, although they do report ≥50% mean reductions in pain measured on the visual analog scale (VAS) from pre-operative baseline to six months in 7/23 (30%) subjects with data ([@bib37]). Combination therapy technique and optimization has been the focus of several case reports and cohort studies in recent years ([@bib10]; [@bib19]; [@bib35]; [@bib46]; [@bib25]), particularly as a salvage therapy for SCS non-responders.

In this case report, we present a long-term, 60-month follow-up of a patient with traumatic spinal cord injury and post-SCI at-level pain who failed conventional pharmacological pain management case before implantation of a chronic PSFS system. This is the first report of PSFS for treatment of post-SCI at-level pain published in the literature. The 60-month follow-up in this case matches or exceeds the follow-up duration reported in all other PSFS studies for intractable back pain identified in the literature. Informed by these findings, a prospective study may be planned to critically assess the utility of PSFS for post-SCI neuropathic pain in a more rigorous investigation.

2. Methods {#sec2}
==========

2.1. Case report {#sec2.1}
----------------

A 26 year old male was brought into our emergency room after being involved in a roll-over motor vehicle accident in July of 2012. The patient was an unrestrained driver, found ejected from the vehicle, unresponsive. He was intubated prior to his arrival, and a chest tube was placed for a large hemothorax in the setting of multiple bilateral rib fractures. After being hemodynamically stabilized, he underwent a thorough trauma evaluation which revealed a three column burst fracture at the level of T4 with radiographic evidence of an epidural hematoma resulting in a complete, ASIA A spinal cord injury.

He was taken to the operating room on July 27, 2012 for T3-4 decompressive laminectomies and posterior instrumented fusion from T2-T6. Following the procedure, he developed severe, debilitating neuropathic pain located in the center of his back, corresponding to his level of injury. After failing all conservative measures, he was introduced to neuromodulation through our pain management colleagues and underwent a PSFS trial in September of 2013. His symptoms were characterized using a Visual Analogue Scale (VAS) for pain with a pretrial score of 10/10. His daily opioid use averaged 45 mg morphine equivalent daily dose (MEDD).

At the conclusion of the trial, our patient reported a significant improvement of his neuropathic pain and subsequently underwent permanent implantation of two octrode leads (Abbott Medical, Plano, TX, USA) connected to a right flank rechargeable pulse generator on November 6, 2013.

2.2. Literature review {#sec2.2}
----------------------

The authors performed a review of the literature by searching PubMed and Embase databases for primary research articles with the search terms: "spinal cord injury" or "chronic pain" or "back pain" and combinations of the following phrases "peripheral nerve stimulation", "peripheral subcutaneous nerve stimulation", "peripheral nerve field stimulation", "subcutaneous targeted stimulation", "subcutaneous targeted neurostimulation", or "stimulation". Out of a total of 37 identified articles referencing SCI or chronic pain treated with PSFS, 14 articles fulfilled our inclusion criteria of treating chronic back pain with PSFS ([Table 1](#tbl1){ref-type="table"}). Articles using combination therapy of SCS and PSFS were excluded, as were articles where PSFS was used to treat other regions of pain excluding the back.

3. Results {#sec3}
==========

3.1. Case report {#sec3.1}
----------------

Following the implantation of the PSFS, our patient reported instantaneous relief of his pretrial pain with a VAS score of 1/10. Ideal stimulation programming was achieved after approximately 6 separate adjustments. At his most recent follow up, over 5 years post-implantation, he continues to report 100% reduction in his pain and complete cessation of all opioid use. His current programming settings are: Frequency of 50 Hz (Hz), Pulse Width of 350 μs (μsec), Amplitude of 0.00 miliamps (mA), Comf of 7.70 mA, and Perc of 4.50 mA.

3.2. Literature review {#sec3.2}
----------------------

We identified 14 published studies where PSFS was investigated for the treatment of chronic back pain in a total of 260 patients ([Table 1](#tbl1){ref-type="table"}). The first published reports of PSFS for intractable back pain were small retrospective reviews of patient records and case series ([@bib22]; [@bib44]; [@bib28]; [@bib42]; [@bib45]; [@bib58]). In these first six studies, a total of 25 patients underwent permanent implantation of PSFS systems. The leading pain etiology for these patients was failed back surgery syndrome (FBSS) (n = 18), followed by chronic low back pain (CLBP) (n = 3), costoverterbral angle tenderness (CVAT) (n = 1), post-lobectomy pain (n = 1), paravertebral pain of unknown origin (n = 1), and severe lumbo-sacral spondylo-arthrosis (n = 1) ([Table 1](#tbl1){ref-type="table"}). Patients were followed for a minimum of 1 year -- with the exception of [@bib58] -- and all reported significant reductions in VAS ratings after PSFS compared to baseline for each patient, with some patients achieving 100% pain relief at 1 year ([Table 1](#tbl1){ref-type="table"}).

A retrospective review by [@bib58] reported results in 13 patients at a 6.5-month average follow-up timepoint, where group mean VAS pain ratings improved from 7.42 ± 1.16 at baseline to 3.92 ± 1.72 at last follow-up. In addition to improvements in significant improvements in pain ratings, 7 of 13 patients significantly reduced oral opioid consumption at last follow-up ([@bib58]).

[@bib47] published the first multicenter review of PSFS in 111 patients with focal, non-cancer pain, with 70 individuals classified as chronic back pain patients (FBSS: n = 37, CLBP: n = 29; thoracic back pain: n = 4). After three months of stimulation, PSFS significantly reduced pain intensity measured on the 11-point numerical rating scale (NRS) by ≥ 50% in all 111 patients. Patients diagnosed with FBSS saw their NRS scores reduce from 8.0 ± 1.4 at pre-implant baseline to 3.3 ± 2.1 at 3-month follow-up. Chronic low back pain patients saw similar mean improvements in NRS scores (8.3 ± 0.9 to 4.2 ± 2.2), and the smaller thoracic pain cohort reported the greatest improvement from baseline (8.8 ± 1.5 to 2.5 ± 0.6) over the same follow-up period.

[@bib59] published a larger, prospective, observational study of PSFS for a range of different pain conditions in 100 patients, 40 of whom with occipital/facial pain, 44 with lumbosacral pain, 8 with thoracic pain, 5 with groin/pelvic pain, and 3 with abdominal pain. Of the 100 chronic pain patients who underwent implantation of PSFS systems, 69% reported relief \>50% at an average follow-up of 8.1 (±4.7) months ([@bib59]). Mean NRS scores were improved 4.2 ± 2.5 points at following PSFS, and 72% of patients were able to reduce their opioid consumption.

Two retrospective reviews in 24 patients with post-laminectomy syndrome (PLS) (n = 18) and FBSS (n = 6) reported similarly significant reductions pain rating scores at 1 year, and 4.5-month (range 2--9 months) follow-up, respectively ([@bib62]; [@bib11]). While 88.9% (16/18) of PLS patients were able to reduce (n = 5) or stop (n = 11) oral opioid consumption at 1 year, only 1 (16.7%) patient in the FBSS cohort successfully reduced their opioid intake after an unspecified period of time.

Reviews from the Yakovlev and Burgher groups were followed by two larger prospective observational studies of 60 total patients with lumbosacral pain (n = 40) or thoracic pain (n = 20) ([@bib26]; [@bib36]). After 6 moths of PSFS, patients with lumbosacral pain reported a mean reduction in pain scores of 44% \[baseline VAS 7.6 ± 1.52 (n = 40) to follow-up VAS 4.36 ± 2.31 (n = 28)\] ([@bib26]). At 1-year follow-up, patients receiving PSFS for thoracic pain reported mean reduction in pain scores of 72% \[baseline NRS 7.75 ± 1.4 to follow-up 2.25 ± 2.14 (n = 17)\], with 10 (50%) patients able to reduce analgesic consumption ([@bib36]).

[@bib34] published the only randomized controlled study of PSFS. This multicenter study was designed to gather safe and efficacy data for PSFS in management of chronic back pain in 44 patient reporting predominantly axial pain (cervical, dorsal, lumbosacral pain), 30 of whom went on to participate in Phase 1 of the study ([@bib34]). In phase I, patients were randomized to one of four stimulation groups -- minimal, sub-threshold, low frequency, and standard stimulation -- for a period of 4--8 days, after which they would crossover to a subsequent stimulation paradigm, randomly and in a blinded fashion. Significant improvements in pain reduction between the four groups were seen in relation to increasing stimulation intensity (increased frequency and pulse-width) ([@bib34]). Twenty-four (80%) patients responded to therapy (\>50% reduction in pain score during any of the three active stimulation periods) and were enrolled in Phase II of the study, an open-label stimulation phase. After 1-year follow-up during Phase II, 16 (69%) patients were still classified responders, and mean VAS decreased from 7.8 ± 1.1 at baseline to 2.5 ± 2.4 at last follow-up ([@bib34]).

Only one identified study reports follow-up data on PSFS over three years, a recent retrospective review of 6 FBSS patients by [@bib14]. In this study, patients were followed 60-months after implantation, with significant reductions in VAS reported at long-term follow-up (4.66) compared to pre-operative baseline (9.66). The authors note pain scores were most improved in a subset of patients with a lumbosacral component of FBSS pain.

4. Discussion {#sec4}
=============

Peripheral subcutaneous field stimulation (PSFS) has become an increasingly popular therapeutic option in difficult-to-treat cases of focal, intractable pain in recent years ([@bib34]; [@bib15]). PSFS requires stimulation of neuropathic cutaneous afferent fibers in a region of chronic pain, as opposed to identified nerves and anatomical central nervous system structures in PNS and SCS, respectively, meaning placement is based solely on location of maximal pain (the so-called "epicenter of pain") ([@bib15]; [@bib22]). Accurate subcutaneous placement of low-frequency stimulation electrodes over an epicenter of pain has been shown to significantly reduce pain felt in the entire region ([@bib40]). As a result, lead placement accuracy and insertion depth play pivotal roles in ensuring successful nociceptive pathway targeting and significant patient outcomes ([@bib1]; [@bib23]). The flexibility in region-specific placement, rather than anatomically-informed placement, may allow patients who suffer from axial back pain, for example, where conventional SCS is less effective, to experience pain relief with PSFS alone ([@bib34]). The additive ability of PSFS -- to create combination therapy for poor responders to SCS -- yields an additional benefit to the procedure as a salvage therapy in the most treatment-refractory cases of pain ([@bib10]; [@bib30]).

4.1. Limitations {#sec4.1}
----------------

Lack of prospective, observational, randomized controlled studies in the literature is certainly concerning, as is the noticeable lack of basic research on PSFS mechanisms of action in treating chronic pain. It is possible that case series amplify the treatment affect and mitigate complication rates.

4.2. Adverse events {#sec4.2}
-------------------

Adverse events in PSFS have been reported in the literature in 9%--24% of patients ([@bib50]), with the most commonly reported hardware-related events being lead migration and dislocation (13%), lead fracture and/or equipment failure (2%--5%), and the most commonly reported procedure events being infection (1%--6%) and lead erosion (5%) ([@bib47]; [@bib59]; [@bib26]; [@bib50]).

5. Conclusion {#sec5}
=============

Spinal cord injury (SCI) is a devastating diagnosis which carries significant physiologic, psychologic, and economic burden for those who are affected. Healthcare for these individuals requires a holistic approach in order to maximize the potential for recovery. Research efforts have historically been focused on physical rehabilitation and neurologic outcomes with ongoing advancements in neuroprotective and regenerative therapies ([@bib60]). Continued progress in these technologies is paramount, yet, recent literature has shifted focus toward efforts to improve patient-reported, subjective outcomes.

Functional procedures have the potential to impact multiple SCI-injury related sequelae including pain, autonomic dysregulation, and bladder function. Modulation of the nervous system via electrical stimulation has provided promising alternatives to the current standard approaches utilized in chronic pain management. Our case supports the use of PSFS in the treatment of at-level SCI-injury related pain and provides long-term follow up as evidence to suggest its durability and future therapeutic potential.
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[^1]: CLBP: chronic low back pain; FBSS: failed back surgery syndrome; NRS: numerical rating scale; PNFS: peripheral nerve field stimulation; PNS: peripheral nerve stimulation; PSFS: peripheral subcutaneous field stimulation; SQ PNS: subcutaneous peripheral nerve stimulation; STN: subcutaneous targeted neurostimulation; STS: subcutaneous targeted stimulation; VAS: visual analog scale.
